ACTIVE RESEARCH

The MASTER-2 trial pioneers the use of measurable residual disease (MRD) to modulate type and intensity of therapy for patients with newly diagnosed multiple myeloma. This trial studies deferral of transplantation for patients who achieve MRD negativity, the use of an anti-BCMA bispecific T-cell engager for patients MRD positive, and MRD-guided fixed duration therapy.

The FASTER trial studies whether a combination of anti-CD38 antibody and an BCMA-directed bispecific T-cell engager can outperform autologous stem cell transplantation and anti-CD38 antibody plus lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

The IMPEDE trial explores the concomitant use of anti-CD38 and anti-SLAMF7 monoclonal antibodies in combination with pomalidomide for treatment of relapsed and refractory multiple myeloma

The COMMANDER trial explores combinations with Iberdomide, an oral agent belonging to a new class of drugs, the CELMoDs, with the objective to eliminate measurable residual disease (MRD) in patients who completed autologous stem cell transplantation.